De Roock W. Lancet Oncol. 2010
773
tumor samples with quality for DNA analyses
KRAS
299/747 (40%)
C12 C13 C61 C146 Doub
70%
20%
5%
4%
1%
PI3K
108/743 (14%)
E9
E20 Doub
65%
22%
17%
BRAF
36/761(5%)
V600E D549
97%
1%
NRAS
17/644 (3%)
C12
C13
C61
23%
5%
12%
Significative association between OUTCOME and
KRAS, PI3K E20, BRAF and NRAS MUT.
26
